[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2624577T3 - Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea - Google Patents

Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea Download PDF

Info

Publication number
ES2624577T3
ES2624577T3 ES12181773.8T ES12181773T ES2624577T3 ES 2624577 T3 ES2624577 T3 ES 2624577T3 ES 12181773 T ES12181773 T ES 12181773T ES 2624577 T3 ES2624577 T3 ES 2624577T3
Authority
ES
Spain
Prior art keywords
oxybutynin
clonidine
sialorrhea
agonist
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12181773.8T
Other languages
English (en)
Inventor
Alan Geoffrey Roach
Paul Goldsmith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orient Pharma (Samoa) Co Ltd
Original Assignee
Orient Pharma (Samoa) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0602855A external-priority patent/GB0602855D0/en
Priority claimed from GB0602857A external-priority patent/GB0602857D0/en
Application filed by Orient Pharma (Samoa) Co Ltd filed Critical Orient Pharma (Samoa) Co Ltd
Application granted granted Critical
Publication of ES2624577T3 publication Critical patent/ES2624577T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una formulación líquida que comprende: a) clonidina; b) oxibutinina; y c) excipientes.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12181773.8T 2006-02-13 2007-02-12 Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea Active ES2624577T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0602855 2006-02-13
GB0602855A GB0602855D0 (en) 2006-02-13 2006-02-13 The Treatment Of Sialorrhoea
GB0602857A GB0602857D0 (en) 2006-02-13 2006-02-13 The treatment of sialorrhoea
GB0602857 2006-02-13

Publications (1)

Publication Number Publication Date
ES2624577T3 true ES2624577T3 (es) 2017-07-17

Family

ID=37944141

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12181773.8T Active ES2624577T3 (es) 2006-02-13 2007-02-12 Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea
ES07705370.0T Active ES2442694T3 (es) 2006-02-13 2007-02-12 Combinación de un agonista de los receptores alfa 2 (clonidina) y un agente antimuscarínico (oxibutinina) para el tratamiento de la sialorrea

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07705370.0T Active ES2442694T3 (es) 2006-02-13 2007-02-12 Combinación de un agonista de los receptores alfa 2 (clonidina) y un agente antimuscarínico (oxibutinina) para el tratamiento de la sialorrea

Country Status (13)

Country Link
US (2) US8481583B2 (es)
EP (2) EP2526943B1 (es)
JP (2) JP5296557B2 (es)
KR (1) KR101370096B1 (es)
AU (1) AU2007216320B2 (es)
CA (1) CA2642850C (es)
DK (2) DK2526943T3 (es)
ES (2) ES2624577T3 (es)
HK (1) HK1129595A1 (es)
MY (1) MY145817A (es)
NZ (1) NZ570492A (es)
PT (2) PT2526943T (es)
WO (1) WO2007093824A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5296557B2 (ja) * 2006-02-13 2013-09-25 オリエント ファーマ（サモア）カンパニー，リミティド 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ
GB0715790D0 (en) * 2007-08-13 2007-09-26 Summit Corp Plc Drug combination for the treatment of sialorrhoea
US20090246256A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
KR20110114552A (ko) * 2009-02-11 2011-10-19 헤글런드, 에이.에스. 금연을 목적으로 하는 니코틴의 구강 흡수용 조성물
RU2572692C2 (ru) * 2009-05-15 2016-01-20 Рекро Фарма, Инк. Сублингвальные композиции дексмедетомидина и способы их применения
WO2013090278A2 (en) 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
KR20240031326A (ko) 2016-12-31 2024-03-07 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
JP7274475B2 (ja) 2017-07-20 2023-05-16 セインダ ファーマシューティカル グアンジョウ コーポレイション 近視の処置のための組成物および方法
CN114983980A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
AU2020316013A1 (en) 2019-07-19 2022-02-17 Arx, Llc Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312879A (en) * 1980-08-14 1982-01-26 Richardson-Merrell Inc. Clonidine and lofexidine as antidiarrheal agents
US5578295A (en) * 1995-04-28 1996-11-26 The Procter & Gamble Company Oral care compositions comprising certain substituted diphenyl ethers
WO1999063997A1 (en) * 1998-06-11 1999-12-16 Arthur Janov Use of clonidine for treatment of addictions, epilepsy, sleep disorders, eating disorders and migraines
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
US6545046B2 (en) * 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
JP2006515607A (ja) * 2003-01-22 2006-06-01 ファイザー・ヘルス・アクチエボラーグ 泌尿器障害を治療するためのトルテロジン及び他の抗ムスカリン様作用剤の用量の減少
JP5296557B2 (ja) * 2006-02-13 2013-09-25 オリエント ファーマ（サモア）カンパニー，リミティド 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production

Also Published As

Publication number Publication date
HK1129595A1 (zh) 2009-12-04
PT1986642E (pt) 2014-01-30
CA2642850C (en) 2015-06-30
EP2526943B1 (en) 2017-03-22
AU2007216320B2 (en) 2010-10-28
DK1986642T3 (da) 2014-02-03
US8481583B2 (en) 2013-07-09
US20120316213A1 (en) 2012-12-13
MY145817A (en) 2012-04-30
US20090221659A1 (en) 2009-09-03
AU2007216320A1 (en) 2007-08-23
JP2013144704A (ja) 2013-07-25
JP5744947B2 (ja) 2015-07-08
NZ570492A (en) 2011-08-26
JP2009526829A (ja) 2009-07-23
EP1986642B1 (en) 2013-11-13
PT2526943T (pt) 2017-05-22
KR20090019765A (ko) 2009-02-25
DK2526943T3 (en) 2017-05-15
EP1986642A1 (en) 2008-11-05
KR101370096B1 (ko) 2014-03-04
WO2007093824A1 (en) 2007-08-23
US8658683B2 (en) 2014-02-25
JP5296557B2 (ja) 2013-09-25
ES2442694T3 (es) 2014-02-12
EP2526943A1 (en) 2012-11-28
CA2642850A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
ES2624577T3 (es) Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ES2483725T3 (es) Composición básica cosmética y su uso
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
ES2477465T3 (es) Fumigantes de espinosina
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
ES2525918T3 (es) Proceso para la fabricación de Nicorandil
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
PE20142372A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
ES2527828T3 (es) Aparato para aplicar tracción a un pene
ES2564172T3 (es) Utilización de una composición cosmética para el cuidado de las pieles grasas
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
ES2484721T3 (es) Mezcla fluidizante para composición hidráulica
ECSP066338A (es) Nueva composición que comprende rosiglitazona y otro agente antidiabético
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.
AR059357A1 (es) Formulaciones farmaceuticas
ES2513516T3 (es) Método para un sellado con fibrina mejorado
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática